In summary, the collective evidence from various studies, including those exploring dual agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR), demonstrates unprecedented improvements in diabetes and body weight compared to GLP-1RA treatment alone. Here, GIPR is linked to diabetes mellitus.